Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

What we know so far
CNBC World (Nov 18, 20:02): The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
CNBC Top News (Nov 18, 20:02): The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.
Headlines on this story
- Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy – CNBC World
- Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy – CNBC Top News
Risk warning: This article is for information only and is not investment advice. Trading forex, CFDs, stocks and crypto carries a high risk of losing money. Prices move fast – check live quotes before you trade.

